The joumal uses Crossref ited-by service counts times cited of published aricles. Citedby allows Crossref members to find out who is citing their conten. This is the Citing Article List of “Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity?”.
|
No. |
Publication Date |
Citing Article |
|
1 |
2026 |
Mario Balsa Pena, David Díaz Gimeno, José Carlos Ruffinelli Rodríguez, Cristina Santos Vivas. Actionable subgroups (II): HER2+, NTRK/RET/ALK and MSI-H/TMB high, Revisiones en Cáncer. 2026; https://doi.org/10.20960/revcancer.00135 |
|
2 |
2025 |
Evgeny N. Imyanitov, Elena V. Preobrazhenskaya, Natalia V. Mitiushkina. Overview on biomarkers for immune oncology drugs, Exploration of Targeted Anti-tumor Therapy. 2025; 6: 1002298. https://doi.org/10.37349/etat.2025.1002298 |
|
3 |
2025 |
Irem Yenidogan, Uri Tabori, Anirban Das. Harnessing mismatch repair deficiency for therapeutic targeting in cancers, Expert Opinion on Therapeutic Targets. 2025; 29: 757. https://doi.org/10.1080/14728222.2025.2608031 |
|
4 |
2026 |
Angela Damato, Riziero Esposito Abate, Simona Tessitore, Daniela Frezzetti, Monica Rosaria Maiello, Dario Righelli, Francesca Bergamo, Lorenzo Antonuzzo, Guglielmo Nasti, Filippo Pietrantonio, Giuseppe Tonini, Tiziana Latiano, Roberto Bordonaro, Gerardo Rosati, Elisa Giommoni, Francesco Iachetta, Mario Larocca, Evaristo Maiello, Sara Lonardi, Alessandra Romagnani, Giuseppe Maglietta, Antonella De Luca, Nicola Normanno, Carmine Pinto. First-line Nivolumab plus FOLFOXIRI/Bevacizumab in advanced RAS/BRAF-mutated colorectal cancer: efficacy, safety and biomarker discovery from the phase II NIVACOR trial, Nature Communications. 2026; https://doi.org/10.1038/s41467-026-70620-y |
|
5 |
2025 |
Sigfredo E Romero-Zoghbi, Evita Krumina, Fernando López-Campos, Felipe Couñago. Current and future perspectives in the management and treatment of colorectal cancer, World Journal of Clinical Oncology. 2025; 16: https://doi.org/10.5306/wjco.v16.i2.100807 |
|
6 |
2025 |
Ali Rahimi, Zeinab Baghernejadan, Ali Hazrati, Kosar Malekpour, Leila Nejatbakhsh Samimi, Alireza Najafi, Reza Falak, Hossein Khorramdelazad. Combination therapy with immune checkpoint inhibitors in colorectal cancer: Challenges, resistance mechanisms, and the role of microbiota, Biomedicine & Pharmacotherapy. 2025; 186: 118014118014. https://doi.org/10.1016/j.biopha.2025.118014 |